Brief: Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus Assay
16/12/2021 12:30
Dec 16 (Reuters) - Applied BioCode Corp 6598.TW :
* APPLIED BIOCODE OBTAINS EMERGENCY USE AUTHORIZATION FOR
COV-2
FLU PLUS ASSAY
* APPLIED BIOCODE CORP - RECEIVED EMERGENCY USE
AUTHORIZATION
(EUA) FROM US FDA FOR ITS BIOCODE® COV-2 FLU PLUS ASSAY
Source text for Eikon: ID:nBw2QfXqba
Further company coverage: 6598.TW
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Applied BioCode
See all newsBrief: Applied BioCode Announces Retirement Of CEO Chris Bernard
Brief: Applied BioCode Announces Distribution Agreement With Medline Industries
Brief: Applied Biocode Announces Exclusive Partner Distribution Agreement With Hardy Diagnostics, Further Broadens Reach Of Biocode® Mdx-3000 System Into Hospitals And Reference Laboratories In The United States
Brief: Applied BioCode Obtains Emergency Use Authorization for CoV-2 Flu Plus Assay